For monitoring of individuals taking GLP-1s, DXA could be considered yearly or every 2 years, although such a timeline may impede the identification of early muscle loss and institution of appropriate interventions
In contrast, anorexigenic intestinal peptides as peptide YY (PYY), pancreatic polypeptide (PP), GLP-1, oxyntomodulin and cholecystokinin are low during the fasting period, and their level increases after a meal, and some of them are released proportionally to the amount of calories ingested (Reviewed in [127])
When prescribed by your healthcare provider, GLP-1 weight loss medications could qualify for payment using your pre-tax FSA or HSA funds, regardless of their prescribed purpose
Collected variables included demographics, diabetes duration, BMI, HbA1c, BMI z-scores, medication type and dose, and adverse effects